Unknown PHASE4 INTERVENTIONAL 3-arm NCT05952505

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Varicella Vaccine and Measles, Mumps and Rubella Combined Vaccine in Shanghai, China: A Non-inferiority, Open-label, Randomised, Controlled, Phase 4 Trial

Sponsor: China National Biotec Group Company Limited

Conditions Measles Mumps Rubella SARS-CoV-2 Infection Varicella

Interventions Inactivated SARS-CoV-2 vaccine administered alone Inactivated SARS-CoV-2 vaccine coadministered with MMR Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine

Updated 4 times since 2023 Last updated: Jul 17, 2023 Started: Aug 31, 2023 Primary completion: Dec 31, 2023 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Measles and Mumps, this trial is ongoing. The trial is conducted by China National Biotec Group Company Limited and has accumulated 4 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Aug 2025 — Present [monthly]

Unknown PHASE4

Status: Not Yet Recruiting → Unknown
Sep 2024 — Aug 2025 [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
Aug 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China National Biotec Group Company Limited
Shanghai Municipal Center for Disease Control and Prevention

Data source: Shanghai Municipal Center for Disease Control and Prevention

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China